Peptide education
Hexarelin
Hexarelin, also known as examorelin, is a synthetic hexapeptide and the most potent growth hormone secretagogue in its class at the ghrelin receptor. Small human studies confirm it can produce a sharp GH pulse after IV or subcutaneous dosing. What makes hexarelin unusual is that its longer human data argues against the hype: sixteen weeks of twice-daily injections produced a blunting GH response and no significant change in IGF-1, body fat, lean mass, or bone density. The muscle, fat-loss, recovery, and sleep claims built around the name are marketing running ahead of, and in places against, the evidence.
Hexarelin is the strongest GH releaser in its class, and its own human data is the best argument against the hype: the one long study watched the GH response fade while body composition stayed flat. Acute hormone spikes are documented; physique, recovery, and sleep benefits are not, and the sleep study found less deep sleep, not more.
Overview
Quick answer
Hexarelin is not an approved growth hormone replacement product, and it is not the same thing as macimorelin, sermorelin, ipamorelin, CJC-1295, or generic "GH peptide" stacks. The older human literature studied specific experimental routes and doses, while current internet listings often sell research-use or clinic-marketed products with much less finished-product information.
What is hexarelin?
Hexarelin is a synthetic hexapeptide GH secretagogue, INN examorelin, developed as EP-23905 and MF-6003. It stimulates GH release through the ghrelin-receptor system rather than replacing GH, and it is the most potent of the common GHRP-class compounds.
What do people use or discuss it for?
Online, it is sold toward muscle, fat loss, recovery, anti-aging, libido, and general GH optimization. The actual study record covers acute GH release, route comparisons, endocrine feedback, a sleep-lab experiment, and exploratory cardiac imaging: a much smaller list.
What study exposure patterns are reported?
Controlled experimental dosing only: single IV boluses of 0.5 to 2 mcg/kg, a multi-route study spanning IV, subcutaneous, intranasal, and oral exposure, and one 16-week twice-daily subcutaneous run. These describe what was tested, not a public use schedule.
What does the GH pulse mean?
That the receptor responded. Hexarelin has enough human pharmacology to explain the interest, but a hormone spike is a measurement, and the only study that looked past the spike found attenuation and no body-composition change.
Reported practice
Commonly reported protocol
Community secretagogue protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Small human studies reported strong GH responses after experimental hexarelin exposure, including IV dose-response work and a multi-route study.
The multi-route human study reported much lower bioavailability for oral hexarelin than for subcutaneous exposure, which matters when modern product pages gloss over route questions.
A 16-week twice-daily subcutaneous study reported partial, reversible attenuation of the GH response, while the published summary reported no significant change in IGF-1, IGFBP-3, body fat, lean body mass, or bone mineral density.
Human studies reported prolactin, ACTH, and cortisol effects, so hexarelin is not a tidy GH-only wellness tool.
The online market includes research-use listings, clinic marketing, and regulator warnings about unauthorized peptide products, misbranding, contamination, wrong active-ingredient amount, and unknown quality.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Hexarelin raises growth hormone. | This is the best-supported human point. Small studies in healthy volunteers reported acute GH release after IV, subcutaneous, intranasal, and oral experimental dosing, with dose-response data after IV boluses. | Hexarelin acts in the GH secretagogue and ghrelin receptor system, which explains why acute GH release is a plausible and repeatedly observed endocrine effect. | Clinic and vendor discussions often foreground this hormone effect and then advertise broader physique or wellness outcomes that the human studies did not test. | Supported for short-term GH release in small physiology studies. Those studies did not test muscle, fat-loss, recovery, or anti-aging benefit. |
| Hexarelin builds muscle or improves body composition. | The longer human study did not report a significant change in IGF-1, IGFBP-3, body fat, lean body mass, or bone mineral density after 16 weeks of twice-daily subcutaneous exposure. | GH and IGF-1 biology can affect tissue remodeling, which explains why bodybuilding and optimization claims travel with secretagogues. That biology did not become a demonstrated body-composition result in the cited longer study. | Muscle, cutting, recovery, and optimization claims appear in clinic, vendor, and gray-market discussions, usually without controlled outcomes or finished-product verification. | Muscle and body-composition claims remain extrapolations from GH biology, not measured hexarelin outcomes. |
| Hexarelin improves sleep or recovery. | A controlled sleep-endocrine study in healthy volunteers reported reduced slow-wave sleep while GH, ACTH, cortisol, and prolactin increased during the study night. | GH pulses and sleep physiology overlap, which is why sleep and recovery marketing is attractive. The human sleep study works against a simple sleep-improvement claim. | Recovery and sleep language can appear in wellness marketing, but the cited human sleep result points more toward downside than benefit. | The cited human sleep study argues against calling hexarelin a sleep peptide: it found less slow-wave sleep rather than a sleep benefit. |
| Hexarelin improves heart function. | Small acute human cardiac studies reported left ventricular ejection fraction changes after IV hexarelin in selected settings, but they did not show lasting clinical outcomes such as fewer hospitalizations, better exercise capacity, or improved survival. | Separate mechanistic papers describe CD36-linked cardiovascular biology in addition to GH secretagogue receptor activity, giving the cardiac research a clear mechanism to test. | Clinic and vendor material may turn cardiac mechanism into wellness or longevity language, but the human data are short-term imaging signals. | Exploratory cardiac physiology only. These studies do not make hexarelin a heart treatment. |
| Oral hexarelin is a dependable route. | Oral hexarelin was studied experimentally, but the multi-route human study reported very low oral bioavailability compared with subcutaneous exposure. | Peptide stability and absorption are route-dependent questions, not assumptions that follow from receptor activity. | Internet marketing can blur route differences by using the same compound name across oral, injectable, intranasal, and research-use products. | Oral exposure should stay in the historical route discussion, not in public efficacy claims. |
| Hexarelin is safer because it is a peptide or because it releases the body's own GH. | Human studies show endocrine spillover into prolactin, ACTH, and cortisol, plus limited long-term exposure data. The 16-week endocrine follow-up found no chronic pituitary-adrenal or prolactin overstimulation at that studied schedule, but broader safety remains unanswered. | Secretagogue signaling still acts on endocrine systems with feedback, downstream hormones, and off-target physiology. "Peptide" does not make the product sterile, correctly dosed, or clinically safe. | Research-use and clinic-market products add identity, sterility, concentration, endotoxin, storage, and labeling questions that older physiology papers do not answer. | The safety picture is incomplete. Human endocrine effects and gray-market product risks belong in the same risk discussion. |
Bottom line
Main takeaway
Hexarelin is a potent GH-releasing research peptide with no approved product anywhere in the cited record. Its acute hormone effects are documented; its physique and recovery promises are not, and its longest human study points the other way.
In community terms, hexarelin is the strong-but-dirty option: biggest GH spike, most cortisol and prolactin spillover, and the clearest desensitization pattern, which is why community cycles are kept short. None of those conventions came from outcome trials.
The primary base covers acute endocrine pharmacology, route bioavailability, the 16-week attenuation study, the sleep-endocrine experiment, CD36 cardiac biology, and regulator product warnings. The 16-week and sleep studies are the ones the marketing never cites.
Identity
What it is
Hexarelin is a synthetic hexapeptide GH secretagogue, listed as examorelin with development codes EP-23905 and MF-6003. Among the common GHRP-class compounds it is the most potent at the GH secretagogue receptor, which is precisely why it developed a following.
The acute human pharmacology is genuinely solid for its size: IV dose-response work showed dose-dependent GH release peaking around 30 minutes and resolving within hours, and a multi-route study mapped large bioavailability differences, with oral exposure performing poorly. That is the flattering half of the record.
The unflattering half is more informative. Sixteen weeks of twice-daily subcutaneous dosing produced partial, reversible attenuation of the GH response and no significant change in IGF-1, IGFBP-3, body fat, lean mass, or bone mineral density. A controlled sleep study found slow-wave sleep decreased while GH, ACTH, cortisol, and prolactin rose: the opposite of the recovery-peptide pitch.
There is also a legitimate scientific side thread: small cardiac imaging studies and CD36-linked biology gave hexarelin an exploratory cardiovascular rationale. Those were acute signals, not outcomes, and development never produced an approved hexarelin product, so today's supply is entirely research-use and clinic-market material.
How people talk about it online
Clinic and gray-market copy casts hexarelin as the heavy hitter of GH optimization: maximum GH for physique, recovery, and anti-aging goals. The same marketing reliably omits the two human studies that followed people past the first spike.
Community protocol culture has absorbed part of the lesson: hexarelin cycles are described as short, 4 to 8 weeks with breaks, because desensitization is common knowledge among users. That convention acknowledges the attenuation finding while the benefit claims around it remain untested.
Vendor listings make the product look simpler than it is: hexarelin or hexarelin acetate by name, a purity figure, maybe a COA. Regulator warnings about unauthorized peptides cover exactly this channel, and the unanswered questions are lot identity, concentration, sterility, endotoxin, and storage.
Use context
Routes, doses, and cycle patterns
The clearest dosing details come from older human studies: single IV boluses, route-comparison exposure, repeated twice-daily subcutaneous dosing, and overnight sleep-study dosing. Current clinic, vendor, and gray-market sources show how hexarelin is marketed, not a reliable dosing schedule.
Human studies and product labels
Multi-route human GH-release study
- Purpose
- Acute endocrine pharmacology and route comparison
- Context
- Human physiology study
- Route
- IV, subcutaneous, intranasal, and oral
- Amount
- IV 1 and 2 mcg/kg; subcutaneous 1.5 and 3 mcg/kg; intranasal 20 mcg/kg; oral 20 and 40 mg
- Frequency
- Single experimental exposures
- Duration
- Acute sampling period
The study reported marked GH release across studied routes, with much higher bioavailability for subcutaneous exposure than for intranasal or oral exposure. That route difference is one of the clearest details for reading modern claims.
IV dose-response study
- Purpose
- Acute GH dose response
- Context
- Double-blind placebo-controlled human study
- Route
- IV
- Amount
- 0.5, 1, and 2 mcg/kg
- Frequency
- Single bolus
- Duration
- GH response followed for several hours
Healthy adult men had a dose-dependent GH rise, with the peak described around 30 minutes and values returning toward baseline by about 240 minutes. This supports acute endocrine activity, not practical outcome claims.
Intranasal pediatric preliminary study
- Purpose
- Short-stature endocrine-marker exploration
- Context
- Preliminary human study
- Route
- Intranasal
- Amount
- No public amount in the study summary
- Frequency
- Two or three times daily
- Duration
- 7 days
Children with short stature and normal GH secretion had endocrine-marker changes in a short preliminary study. That finding is too limited for routine pediatric treatment or personal use.
Repeated subcutaneous endocrine study
- Purpose
- Longer GH-response and downstream-marker assessment
- Context
- Human endocrine study
- Route
- Subcutaneous
- Amount
- 1.5 mcg/kg
- Frequency
- Twice daily
- Duration
- 16 weeks, with 4-week washout assessment
GH response partially and reversibly attenuated. The published summary reported no significant changes in IGF-1, IGFBP-3, body fat, lean body mass, or bone mineral density, which is directly relevant to physique claims.
Chronic HPA and prolactin follow-up
- Purpose
- Pituitary-adrenal and prolactin safety result
- Context
- Human endocrine follow-up study
- Route
- Subcutaneous
- Amount
- 1.5 mcg/kg
- Frequency
- Twice daily
- Duration
- 16 weeks
The study found no chronic overstimulation of pituitary-adrenal or prolactin secretion at that schedule, while other acute studies still show that hexarelin can affect ACTH, cortisol, and prolactin.
Acute cardiac imaging studies
- Purpose
- Exploratory cardiovascular physiology
- Context
- Small human studies
- Route
- IV
- Amount
- 2.0 mcg/kg in one cited cardiotropic study
- Frequency
- Acute exposure
- Duration
- Short-term imaging assessment
Small studies reported acute left ventricular ejection fraction changes in selected groups. They did not test long-term clinical outcomes.
Sleep-endocrine study
- Purpose
- Sleep and endocrine response
- Context
- Small controlled human study
- Route
- No public route in the study summary
- Amount
- Four 50 mcg administrations during the sleep period
- Frequency
- Four administrations overnight
- Duration
- One sleep period
Slow-wave sleep decreased while GH, ACTH, cortisol, and prolactin increased. This is the opposite of a simple sleep-improvement claim.
Real-world discussion
Community secretagogue protocols
- Purpose
- GH release for recovery and body composition
- Context
- Forums, vendor listings, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Community protocols usually describe 100 to 200 mcg per injection, two to three times daily.
- Frequency
- Two to three times daily in most descriptions
- Duration
- Usually described as shorter runs of 4 to 8 weeks with breaks, because community sources emphasize desensitization with continuous hexarelin exposure.
Hexarelin is treated in community discussion as the strongest but least selective common secretagogue, with the most noted cortisol and prolactin spillover and the clearest desensitization concern, which is why its cycles are described as shorter than ipamorelin or GHRP-2. Human outcome data for marketed uses are absent. Reported as context, not a recommendation.
What varies
- Goal: a GH spike measures acute endocrine response; body composition, sleep, recovery, and cardiac claims require their own outcome data.
- Route: IV, subcutaneous, intranasal, and oral exposure produced different human route-comparison results.
- Amount: study sources use mcg/kg experimental dosing, while vendor and clinic discussions may use product-facing language that may not match study exposure.
- Frequency: repeated twice-daily exposure produced partial GH-response attenuation in the longer endocrine study.
- Product quality: a research-use label or COA leaves identity, sterility, endotoxin, concentration, storage, reconstitution, and shipping questions open.
Human data
Human evidence
Hexarelin's human record is small but unusually honest about its own limits. Acute studies document dose-dependent GH release across IV, subcutaneous, intranasal, and oral routes, with oral bioavailability poor. The one long study, 16 weeks of twice-daily subcutaneous dosing, found the GH response partially attenuating and reported no significant changes in IGF-1, IGFBP-3, body fat, lean mass, or bone density. Separate work documented prolactin, ACTH, and cortisol effects and a reduction in slow-wave sleep, while exploratory cardiac imaging showed acute ejection-fraction changes without clinical outcomes. For physique, performance, recovery, sleep, aging, and heart-treatment claims, there is no supporting outcome data, and some of the closest looks point against them.
Evidence maturity
Hexarelin's human data stop at acute hormone physiology, and its longest study argued against the physique claims the market makes.
1990s IV, subcutaneous, intranasal, and oral studies confirmed acute, dose-dependent GH release with large route differences.
A 16-week twice-daily subcutaneous study showed partial, reversible GH-response attenuation and no significant change in body composition.
Small cardiac imaging studies gave acute signals, and the controlled sleep study found reduced slow-wave sleep rather than a benefit.
Development never produced an approved hexarelin product; current supply is research-use and clinic-market vials with regulator warnings.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Multi-route GH-releasing activity study | Healthy young volunteers | Human physiology study | Investigational experimental dosing | IV, subcutaneous, intranasal, and oral hexarelin exposures were studied, with marked GH release and major route-dependent bioavailability differences. | Acute hormone response cannot show long-term benefit, and oral bioavailability was very low in the study summary. | limited human |
| IV dose-response study | Healthy adult men | Double-blind placebo-controlled physiology study | Investigational experimental dosing | Single IV boluses produced dose-dependent GH release, with a short-lived endocrine response. | The study measured endocrine response, not muscle, fat loss, sleep, recovery, or clinical outcomes. | limited human |
| Mechanistic modulation and hypothalamic-pituitary work | Normal men and selected GH-deficiency or hypothalamic-pituitary cohorts | Human challenge and mechanism studies | Investigational experimental dosing | The studies support hypothalamic and pituitary involvement and show that feedback behavior differs from a simple GHRH-only response. | Mechanism studies help explain signaling, not practical benefits. | limited human |
| Pediatric and age-effect studies | Children with short stature, pubertal children, young adults, and older adults | Preliminary and comparative human endocrine studies | Investigational experimental dosing | Short pediatric and age-comparison work showed endocrine-marker and GH-response differences by population. | The work is small and heterogeneous, so it is too limited for routine pediatric, anti-aging, or diagnostic claims. | weak human |
| Sixteen-week subcutaneous endocrine study | Adults in a longer endocrine exposure study | Human repeated-exposure study | Investigational experimental dosing | Twice-daily subcutaneous exposure led to partial, reversible attenuation of GH response, with no significant change in IGF-1, IGFBP-3, body fat, lean body mass, or bone mineral density in the published summary. | The published summary limits detail, and the findings do not back physique or performance claims. | limited human |
| Chronic HPA and prolactin study | Adults in chronic endocrine follow-up | Human endocrine safety study | Investigational experimental dosing | The study did not find chronic pituitary-adrenal or prolactin overstimulation at the studied twice-daily schedule. | It does not answer broad long-term safety, other schedules, other products, or off-label populations. | limited human |
| Acute cardiovascular studies | Healthy adults, severe GH-deficient adults, and dilated cardiomyopathy patients in small studies | Small acute human imaging studies | Investigational experimental dosing | Some acute left ventricular ejection fraction changes were reported, supporting exploratory cardiovascular physiology. | These studies reported acute physiology signals rather than lasting clinical benefit or cardiovascular outcome improvement. | weak human |
| Sleep-endocrine study | Healthy volunteers | Small controlled human study | Investigational experimental dosing | Slow-wave sleep decreased while GH, ACTH, cortisol, and prolactin rose during the sleep period. | Small size and acute design limit generalization, but the result directly pushes back against sleep-benefit marketing. | weak human |
| Historical diagnostic exploration | Adults with suspected growth hormone deficiency in historical work | Historical diagnostic comparison and registry context | Investigational diagnostic exploration | Hexarelin was historically investigated for adult GH-deficiency testing, while modern approved class-comparator context points to macimorelin rather than hexarelin. | Historical diagnostic exploration shows older testing interest, separate from current access to an approved hexarelin diagnostic product. | weak human |
Cautions
Safety and unknowns
- Hexarelin is not GH-only in human studies; prolactin, ACTH, and cortisol changes appear in the endocrine literature.
- Repeated exposure may blunt the GH response, as seen in the 16-week twice-daily subcutaneous study.
- Sleep marketing deserves special caution because the cited sleep study reported decreased slow-wave sleep.
- Long-term safety for body-composition, recovery, anti-aging, or wellness use was not characterized in the human studies above.
- Current research-use, clinic-market, and gray-market products raise identity, sterility, endotoxin, concentration, labeling, storage, reconstitution, and shipping concerns.
- Regulator warnings for unauthorized peptide products describe risks such as wrong active-ingredient amount, unlisted ingredients, microbiological contamination, endotoxins, and poor manufacturing or storage.
Product quality
A vial label is only a starting point
Hexarelin appears in current internet-facing channels mainly as research-use material, clinic-marketed peptide, or gray-market product rather than as an FDA-reviewed finished drug.
A vial label, CAS number, purity percentage, or COA cannot show that a product matches the material used in human studies or is suitable as a sterile injectable.
Regulator warnings about peptide products are directly relevant to hexarelin-style markets because the practical risks include identity, concentration, contamination, and misleading "research use only" claims.
Identity
Hexarelin, examorelin, acetate forms, and product codes have to match the actual molecule being discussed before evidence can be applied.
Sterility and endotoxin
Injectable-product risk requires more than purity alone; sterile manufacturing, endotoxin control, and representative lot testing matter.
Concentration and dose math
Study dosing used mcg/kg or specific experimental amounts, while vendor-facing vial strengths do not by themselves translate into a safe or evidence-backed schedule.
Storage and handling
Peptide degradation, reconstitution conditions, shipping temperature, and handling can change what a user actually receives.
Labeling and legality
Research-use wording, clinic claims, and sales language do not answer approval, lawful human use, or finished-product quality.
Mechanism
How it is proposed to work
Hexarelin stimulates the GH secretagogue system, which can signal the pituitary GH axis to release growth hormone. It also has separate cardiovascular literature involving CD36-linked biology, which is why some papers discuss cardiac effects apart from GH release alone.
Public pharmacology sources describe examorelin/hexarelin as a peptide ligand in the ghrelin receptor or GH secretagogue receptor family.
Human challenge studies support both pituitary and hypothalamic involvement, rather than a simple one-step hormone release model.
Comparative endocrine work reported prolactin, ACTH, and cortisol changes, which is why a selective GH-only description is too narrow.
CD36-linked cardiovascular papers give the cardiac mechanism a rationale, but small acute imaging studies do not tell whether patients live longer, feel better, avoid hospitalization, or improve exercise capacity.
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is the most potent common GHRP-class agonist at GHS-R1a and also shows CD36-binding activity in cardiovascular models. Its GH response attenuates with repeated exposure, the class's clearest desensitization pattern.
FAQ
Common questions
Why are hexarelin cycles described as shorter?
Because community sources emphasize desensitization: the GH response to hexarelin attenuates with continuous exposure, so typical runs are 4 to 8 weeks with breaks rather than open-ended use.
What does community use look like?
Commonly 100 to 200 mcg per injection, two to three times daily, in those shorter cycles.
Does hexarelin have human evidence?
Human endocrine challenge studies document GH release, but there are no outcome trials for recovery, body composition, or anti-aging. It also carries the class's strongest cortisol and prolactin spillover.
Details
Technical details
Sources
References
- 1.
Ghigo multi-route study. Ghigo et al., 1994, multi-route human study
Human routes, GH response, comparative route bioavailability, oral limitation
- 2.
Mechanism studies. Arvat 1995, Massoud 1995, Loche 1995
Mechanism, feedback modulation, hypothalamic contribution
- 3.
Pediatric and age data. Frenkel 1995 and Bellone 1998
Pediatric preliminary data, puberty/aging caveats
- 4.
Rahim HPA follow-up. Rahim et al., 1999 plus Arvat 1997 endocrine comparison work
Chronic HPA/PRL result, non-selective endocrine effects
- 5.
Cardiac imaging studies. Bisi 1999 and Broglio 2001 human cardiac studies
Acute LVEF findings, GH-independent cardiac hypothesis
- 6.
Frieboes sleep study. Frieboes et al., 2004
Sleep-endocrine findings, reduced slow-wave sleep
- 7.
Diagnostic exploration. Gasperi 1999 plus ClinicalTrials.gov record
Historical adult GHD diagnostic exploration; no posted results on the modern record surfaced here
- 8.
Identity databases. NCATS Inxight and GtoPdb
Identity, aliases, class, development framing
- 9.
CD36 cardiac biology. Bodart 1999, Bodart 2002, Avallone 2006, ghrelin comparison paper
GHSR/CD36 biology and broader mechanism
- 10.
FDA compounding context. FDA 503A, FDA compounding FAQ, FDA compounding Q&A
COA requirement for bulk substances, compounded-drug quality/regulatory context
- 11.
FDA enforcement signals. FDA enforcement and market-signal sources
Unknown quality, misbranding, peptide storefront/blend signals, “research use only” enforcement context
- 12.
Health Canada advisory. Health Canada 2026 peptide advisory
Online peptide risks, contaminants, wrong API amount, research-use label not a legal shield
- 13.
FTC claim guidance. FTC health-product substantiation guidance
Standard for objective health claims and why vendor overclaims matter
- 14.
Research-supplier examples. Research-supplier examples
Research-use-only / not intended for diagnostic or therapeutic use labeling signal
- 15.
Clinic and vendor example. Clinic/vendor marketing example
Shows how clinic and vendor claims stretch the GH signal into broader promises
- 16.
Macimorelin comparator. DailyMed/FDA macimorelin sources
Approved comparator in class; regulatory contrast with hexarelin